Filing Flows

Filing Flows › Companies › Elite Pharmaceuticals › Cash flow

Elite Pharmaceuticals cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow$9.3M in Q1 FY27 · $17.5M over twelve months

Operating cash flow$10.1M
Capital spending−$809K
Free cash flow+$9.3M
Cash / net income1.7×
Cash conversion cycle237 days

Analysis

In Q1 FY27, Elite Pharmaceuticals generated $10.1M of operating cash flow and spent $809K on capital projects, leaving free cash flow of $9.3M. That is $5.3M less than in Q1 FY26 ($14.6M).

Over the twelve months to Jun 30, 2026, operating cash flow was $19.0M; the largest uses were capital spending ($1.5M), net borrowing (+) / repaid (−) ($384K); besides operations, cash came from other financing ($78K); the cash balance rose by $17.2M.

Operating cash flow was $10.1M against net income of $5.9M — 1.7× profit, cash ran ahead of reported earnings. The largest differences: receivables +$9.4M, accrued liabilities −$3.8M, inventory −$2.9M.

Its cash conversion cycle was 237 days (receivables 155 + inventory 110 − payables 28).

Free cash flow

Elite Pharmaceuticals: free cash flow by quarterElite Pharmaceuticals: free cash flow by quarter$1.4MQ2 FY25−$1.1MQ3 FY25$3.2MQ4 FY25$14.6MQ1 FY26$5.0MQ2 FY26−$5.5MQ3 FY26$8.7MQ4 FY26$9.3MQ1 FY27
Operating cash flow less capital spending.
Elite Pharmaceuticals: operating cash flow against capital spendingElite Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$1.5M$92KQ2 FY25−$1.1M$0Q3 FY25$3.9M$754KQ4 FY25$14.8M$218KQ1 FY26$5.1M$103KQ2 FY26−$5.3M$206KQ3 FY26$9.1M$398KQ4 FY26$10.1M$809KQ1 FY27
Latest (Q1 FY27): Operating cash flow $10.1M, Capital spending $809K.

Capital allocation, year by year

Elite Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearElite Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY22: Operating cash flow $6.5MFY22: Capital spending −$499K$6.5MFY22FY23: Operating cash flow $3.3MFY23: Net borrowing $2.2MFY23: Capital spending −$5.7M$5.5MFY23FY24: Operating cash flow −$3.2MFY24: Net borrowing −$350KFY24: Capital spending −$810KFY24FY25: Operating cash flow $7.5MFY25: Net borrowing −$336KFY25: Shares issued $19KFY25: Asset sales $125KFY25: Capital spending −$1.6M$7.6MFY25FY26: Operating cash flow $23.7MFY26: Net borrowing −$380KFY26: Shares issued $319KFY26: Capital spending −$926K$24.1MFY26
Over these 5 years operating cash flow totalled $37.8M; the largest uses were capital spending ($9.6M) and operating cash flow ($3.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$38.9M
Debtnone
Net cash$38.9M

Elite Pharmaceuticals funds itself: free cash flow was $17.5M over the last twelve months, with $38.9M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Elite Pharmaceuticals: sources (+) and uses (−) of cash, Q1 FY27Elite Pharmaceuticals: sources (+) and uses (−) of cash, Q1 FY27Operating cash flow$10.1MCash drawn (+) / kept (−)−$9.1MCapital spending−$809KNet borrowing (+) / repaid (−)−$96KOther financing−$23KShares issued$4K
Elite Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q1 FY27Elite Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q1 FY27Operating cash flow$19.0MCash drawn (+) / kept (−)−$17.2MCapital spending−$1.5MNet borrowing (+) / repaid (−)−$384KOther financing$78K

From profit to cash

Elite Pharmaceuticals: net income to operating cash flow, Q1 FY27Elite Pharmaceuticals: net income to operating cash flow, Q1 FY27Net income$5.9MDepreciation & amortization$253KStock-based pay$28KDeferred taxes$1.3MReceivables$9.4MInventory−$2.9MPayables−$462KAccrued liabilities−$3.8MPrepaid and other assets$428KOperating cash flow$10.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY2715511028237
Q4 FY2612010428196
Q3 FY2613010725212
Q2 FY26987818158
Q1 FY267412528171
Q4 FY256711127152
Q3 FY2512819144276
Q2 FY2510212120203

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27$10.1M−$809K−$96K$4K−$9.1M$9.3M
Q4 FY26$9.1M−$398K−$97K$79K−$8.7M$8.7M
Q3 FY26−$5.3M−$206K−$97K$90K$5.5M−$5.5M
Q2 FY26$5.1M−$103K−$94K—−$4.9M$5.0M
Q1 FY26$14.8M−$218K−$92K—−$10.4M$14.6M
Q4 FY25$3.9M−$754K−$90K—−$3.0M$3.2M
Q3 FY25−$1.1M—−$88K—$1.3M−$1.1M
Q2 FY25$1.5M−$92K−$87K—−$1.2M$1.4M

Elite Pharmaceuticals: income statement and cash flow

Elite Pharmaceuticals, Q1 FY27: revenue $32.4M (-20% year over year), operating margin 23.3%. The chart follows the revenue to costs, profit and cash.

Elite Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.